Human CD7 protein (C-His-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P−) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of the CD7 protein exceeds 95%.
Human SECTM1 (C-Fc) protein is coated at 1 μg/mL (100ng/well). Biotinylated Human CD7 Protein (C-His-Avi) can detect the SECTM1 protein in the dose dependent manner. The ED50 is about 20-60 ng/mL.
Cat #
Size
Price
Quantity
805403
25 ug
$245
805404
100 ug
$595
Product Details
Application
ELISA, BLI
Format
Liquid, Biotinylated
Expression Host
CHO
Target Name
CD7, GP40, TP41, LEU-9, Tp40
Species
Human
Sources
Recombinant Human CD7 (Ala26-Pro180) with C-terminus His-Avi tag is expressed in CHO cell. This protein was site-specifically labeled with Biotin by BirA ligase.
accession number
P09564
Molecular Weight
The protein has a predicted molecular weight of 18 kDa. Under DTT-reducing conditions, it migrates at approximately 30-40 kDa on SDS-PAGE.
Affinity Tag
C-His-Avi
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
CD7, also known as GP40, LEU-9, and TP41, is a 40 kD transmembrane glycoprotein of the immunoglobulin superfamily. It is expressed on thymocytes, T cells, NK cells, myeloid precursor cells, and some leukemia cells. CD7 plays a key role in T cell interactions and early lymphoid development. It activates the PI3K pathway through its intracellular YEEM motif and induces mitogenesis and IL-2 production when treated with anti-CD3 or PMA. CD7 is overexpressed in classical Hodgkin lymphoma and T-cell acute lymphoblastic leukemia (T-ALL), and is a target for CAR T-cell therapies.
Human CD7 protein (C-His-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P−) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of the CD7 protein exceeds 95%.
Human SECTM1 (C-Fc) protein is coated at 1 μg/mL (100ng/well). Biotinylated Human CD7 Protein (C-His-Avi) can detect the SECTM1 protein in the dose dependent manner. The ED50 is about 20-60 ng/mL.
